Patents by Inventor David Paul Humphreys

David Paul Humphreys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9828438
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: November 28, 2017
    Assignee: UCB Pharma S.A.
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Publication number: 20170335003
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 23, 2017
    Inventors: MARK ELLIS, DAVID PAUL HUMPHREYS
  • Patent number: 9803004
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 31, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Pallavi Bhatta, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 9725516
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: August 8, 2017
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Publication number: 20170204200
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH—CH1—X—V1; and b) a polypeptide chain of formula (II): VL-CL-Y—V2 and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.
    Type: Application
    Filed: June 25, 2015
    Publication date: July 20, 2017
    Inventors: Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Paul HUMPHREYS
  • Publication number: 20170198062
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH-CH1-CH2-CH3-X-(V1)p; and b) a polypeptide chain of formula (II): VL-CL-Y-(V2)q and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multi-specific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multi-specific antibody molecule of the present disclosure from a host cell.
    Type: Application
    Filed: June 25, 2015
    Publication date: July 13, 2017
    Applicant: UCB BIOPHARM SPRL
    Inventors: Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Publication number: 20170088603
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 30, 2017
    Inventors: Farnaz FALLAH-ARANI, Robert Anthony GRIFFIN, David Paul HUMPHREYS, Shirley Jane PETERS, Bryan John SMITH, Paul Edward STEPHENS
  • Publication number: 20170081406
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 23, 2017
    Inventors: Farnaz FALLAH-ARANI, Robert Anthony GRIFFIN, David Paul HUMPHREYS, Shirley Jane PETERS, Bryan John SMITH, Paul Edward STEPHENS
  • Patent number: 9587227
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, 170, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: March 7, 2017
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Publication number: 20170029505
    Abstract: The invention relates to multimeric proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune and other disorders.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 2, 2017
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Robert Anthony GRIFFIN, David Paul HUMPHREYS, Shirley Jane PETERS
  • Patent number: 9550973
    Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: January 24, 2017
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Publication number: 20160333105
    Abstract: The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.
    Type: Application
    Filed: May 26, 2016
    Publication date: November 17, 2016
    Inventors: Ralph Adams, Emma Dave, David Paul Humphreys
  • Patent number: 9493558
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a mutant spr protein and wherein the cell comprises a non-recombinant wild-type chromosomal Tsp gene.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 15, 2016
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9493559
    Abstract: The present invention provides a recombinant gram-negative bacterial cell, characterized in that the cell comprises a recombinant polynucleotide encoding DsbC and has reduced Tsp protein activity compared to a wild-type cell.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 15, 2016
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Publication number: 20160311930
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Application
    Filed: July 6, 2016
    Publication date: October 27, 2016
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Publication number: 20160244532
    Abstract: The present disclosure provides a binding protein comprising: a polypeptide heavy chain comprising: VH1—(X1)n-VH2—CH (X2)y wherein VH1 is a first variable domain, VH2 is a second variable domain, CH is a constant domain, X1 represents an amino acid or peptide, X2 represents an Fc region, n is 0 or 1 and y is independently 1 or 2, and a polypeptide light chain comprising: VL1-(X1)n-VL2-C wherein VL1 is a first variable domain, VL2 is a second variable domain, C is a constant domain, X1 represents an amino acid or peptide and n is 0 or 1, wherein the heavy chain and light chain are aligned such that VH1 and VL1 form a first binding domain, and VH2 and VL2 form a second binding domain and wherein: there is a disulfide bond between VH1 and VL1, and/or there is a disulfide bond between VH2 and VL2, and use thereof in treatment.
    Type: Application
    Filed: March 25, 2011
    Publication date: August 25, 2016
    Inventors: Sam Philip Heywood, David Paul Humphreys
  • Publication number: 20160200810
    Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
    Type: Application
    Filed: March 29, 2016
    Publication date: July 14, 2016
    Inventors: MARK ELLIS, DAVID PAUL HUMPHREYS
  • Patent number: 9315770
    Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: April 19, 2016
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9309327
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: April 12, 2016
    Assignee: UCB Pharma S.A.
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Publication number: 20160031974
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 4, 2016
    Inventors: Ralph Adams, Pallavi Bhatta, Sam Philip Heywood, David Paul Humphreys